A comparative pharmaco- clinical study of eranda mool(Ricinus communis Linn.) in the management of Aamvata and Vatarakta
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Subjective Parameter- Grading will be done with signs and symptoms of both Amavata and Vatarakta respectively.
研究概览
简要总结
In this trial we are selecting patients of Amavata and Vatarakta separately in two groups, In which we will do intervention study of study with drug Eranda mool in the form of Kwath preparation, with the Dose of 50 ml. BID. Assessment will be done on the subjective and objective parameters for both the diseases individually.
Route of administration - ORAL
Follow up - Day 15, Day30 while taking medicine and after 15 days after stopping of medicicne.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 30.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Patients with written consent, 2.Having clinical features of Amavata or Vatarakta, 3.Patients fulfilling subjective and objective criteria like sandhi shool, shotha, sandhi stabhdhata etc.
- •in amavata and Sandhi graha, twaka vaivrnaya, raga etc.
- •in vatarakta.
排除标准
- •1.Patients below 30 and above 70 years of age
- •Pregnant and lactating mothers
- •Patients with serious systemic illness
- •Patients with complications of Amavata and Vatarakta.
结局指标
主要结局
Subjective Parameter- Grading will be done with signs and symptoms of both Amavata and Vatarakta respectively.
时间窗: After one month intervention of Erandamool kwatha orally and 15 days after stopping of medicine
RA Factor, CRP, ESR for Amavata and Uric Acid levels for Vatarakta
时间窗: After one month intervention of Erandamool kwatha orally and 15 days after stopping of medicine
次要结局
- Subjective Parameter- Grading will be done with signs and symptoms of both Amavata and Vatarakta respectively.(RA Factor, CRP, ESR for Amavata and Uric Acid levels for Vatarakta.)